Abstract. The present study investigated the internalization behavior of the constitutively active mutant (CAM) N111G of angiotensin II type 1 (AT 1 ) receptor and correlated the result with the mechanism of the constitutive activity of the mutant. The inverse agonist activity of valsartan, losartan, candesartan, and telmisartan was also examined by inositol phosphate (IP) accumulation study as well as receptor-internalization assay. Both wild-type (WT) and N111G mutant receptors were transiently expressed in COS-7 cells and the binding affinities towards the agonist and these four AT 1 antagonists were determined. Production of total IP was measured in the presence and absence of the compounds. The agonist-induced receptor internalization of both WT and N111G mutant receptors was also investigated. Although the mutant showed similar binding characteristics with agonist and the antagonists used as WT, the internalization of the mutant was much lower (19.56 ± 2.87%) than that of the WT receptor (74.63 ± 1.00%). Internalization of the mutant significantly increased (63.22 ± 0.03%) in the presence of valsartan, which also showed significant inverse agonist activity in the N111G mutant. The results indicate that internalization of CAM N111G of the AT 1 receptor is induced by the use of valsartan, which may be an important characteristic of inverse agonist activities of AT 1 antagonists in N111G.
Introduction
G-protein coupled receptors (GPCRs) form one of the largest protein families, with several hundred members in humans (1) . Despite the wide variety of ligands and physiological roles, all these receptors are structurally characterized by seven transmembrane domains and most of them are thought to share common activation and desensitization mechanisms. Angiotensin II (Ang II) receptors are members of the GPCR superfamily. Two subtypes of Ang II receptors have been identified (2, 3) and pharmacologically characterized: Ang II type 1 (AT 1 ) and type 2 (AT 2 ) receptors (4) . Interaction of Ang II with the AT 1 receptor induces vasoconstriction, sodium reabsorption, and stimulation of aldosterone release (5) .
Mutagenesis studies of the AT 1 receptor have recently identified amino acid residues important in the binding of the natural ligand Ang II and non-peptide antagonists. A conserved residue, Lys 199 in the fifth transmembrane domain (TMD V) of the AT 1 receptor, has recently been reported to be crucial for the binding of both peptide (6) and non-peptide (7) ligands. Ang II contains two residues, Tyr 4 and Phe
8
, which are essential for agonism (8) . The activation of AT 1 receptor from the basal state requires an interaction between Asn 111 in TMD III of the AT 1 receptor and the Tyr 4 residue of Ang II (9) . This shows the importance of Asn 111 residue in TMD III of the AT 1 receptor. No naturally occurring, constitutively active mutant (CAM) of AT 1 receptors have been reported, but engineered mutation of the Asn 111 residue to glycine (N111G) results in constitutive activation of the AT 1 receptor (8) . In the wild-type (WT) AT 1 receptor, interaction of Tyr 4 of Ang II with Asn 111 in the receptor appears to act as the trigger to convert the inactive state (R) to the active state (R*) and allow receptor activation. Small side chain substitution (glycine) of Asn 111 in the AT 1 receptor presumably releases this conformational switch, allowing constitutive activity and removing the requirement of Tyr 4 in Ang II for maximal receptor activation.
Agonist binding to a GPCR induces conformational changes in the receptor, leading to activation of Gαβγ heterotrimers (10) . One function of the activated Gproteins is to activate GPCR kinases (GRKs) that in turn phosphorylate the specific receptor for desensitization. Subsequently, β-arrestins bind to the GRK-phosphorylated motifs of the receptor and induce the receptor internalization. This homologous GPCR internalization is agonist-specific and GRK-dependent. This type of feedback regulation is conventional because it requires activation of classic G-proteins (11 -13) . Homologous internalization of GPCRs can also take place through a β-arrestin-independent pathway. Initially, internalization of the GPCRs was viewed as a means to uncouple the receptor from its signaling components, thereby dampening the overall response (14 -17) . The results of many studies indicate that the itinerary of the internalized GPCR is receptor-and cell-specific (18) . At least four pathways of agonist-induced internalization of GPCRs exist (19, 20) , and they may be cell-type specific. The classical GPCR internalization pathway involves GRKs, β-arrestin, clathrin-coated pits, and the GTPase dynamin and is exemplified by the β 2 -adrenergic receptor (11, 19 -24) .
Thus the present study was designed to examine the binding profiles of both WT and the N111G mutant of AT 1 receptors with the AT 1 -receptor agonist Ang II and AT 1 -receptor blockers (ARBs), valsartan, losartan, candesartan, and telmisartan. We also determined total inositol phosphate (IP) accumulation by the cells expressing specified receptors and showed the inverse agonist activity of the ARBs used in this study in the N111G mutant. Finally, we examined the internalization of the specified receptors and correlated the result with the mechanism of constitutive activity of the N111G mutant.
Materials and Methods

Drugs
Ang II used in the study was purchased from Peptide Institute, Inc., Osaka. 
Site-directed mutagenesis
The synthetic rat AT 1 -receptor gene, cloned in the shuttle expression vector pMT-2, was used for expression and mutagenesis, as described in earlier studies (25) . The mutant was prepared by the polymerase chain reaction (PCR) method with the QuichChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). DNA sequence analysis was done to confirm the mutation.
Cell culture, transfection, and membrane preparation COS-7 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin in 5% CO 2 at 37°C. The WT and mutant AT 1 receptors were transfected into COS-7 cells using Lipofectamine TM 2000 according to the manufacturer's protocol (Invitrogen Life Technologies, Rockville, MD, USA). To express the AT 1 receptor protein, 12 μg of purified plasmid DNA/10 7 cells was used in the transfection. Transfected COS-7 cells that had been cultured for 48 h were harvested with ice-cold phosphatebuffered saline (PBS), pH 7.4; washed by HBSS with 1.5% 0.5 M EDTA; 0.15% 50 mg/ml PMSF, and 0.15% 2 mg/ml aprotinin; and finally suspended in 0.25 M sucrose solution containing 1.5% 0.5 M EDTA, 0.15% 50 mg/ml PMSF, and 0.15% 2 mg/ml aprotinin. The cells were then disrupted by Polytron Homogenizer for 10 s. The mass was centrifuged at 4°C for 5 min at 1260 × g and the supernatant was ultra centrifuged at 4°C for 20 minutes at 30,000 × g. The resulting pellets were suspended in binding assay buffer and used for the binding experiments. The protein contents of the membranes were measured by the method of Lowry et al. (26) using bovine serum albumin as the standard.
Radioligand binding assay
Binding assays for WT and N111G mutant of AT 1 receptors were carried out in an incubation tube that contained 10 μg of membrane protein, [
angiotensin II, unlabeled drug as required, and binding buffer containing 20 mM phosphate buffer, 100 mM sodium chloride, 20 mM magnesium chloride, 1 mM EGTA, and 0.2% BSA, pH 7.4 in a final volume of 125 μl. Both saturation and competition binding assays were carried out as described previously (27, 28 -angiotensin II and unlabelled drugs for 1 h at 25°C. The incubation was terminated by rapid filtration under vacuum through Whatman GF/C filters that had been presoaked in 0.5% polyethyleneimine followed by three times washing with ice-cold 50 mM Tris HCl (pH 8.0). The bound ligand fraction was determined from the counts/min remaining on the membrane.
IP accumulation assay
COS-7 cells at about 90% confluence in 10-cm dishes were seeded into 24-well plates. The cells were then transfected with plasmid DNA of both the WT and N111G mutant AT 1 receptors. At 24 h after transfection, the cells were labeled with 1 μCi/ml [ 3 H]myo-inositol in DMEM and incubated for 20 h at 37°C. The cells were washed with Hank's buffered salt solution (HBSS) and exposed with HBSS containing 20 mM phosphate buffer and 20 mM LiCl, pH 7.4. The cells were incubated for 30 min at 37°C. Agonist and four ARBs were added to each well and incubation continued for an additional 1 h at 37°C. At the end of the incubation, the medium was removed, and the total soluble IP was extracted from the cells by the perchloric acid extraction method as described previously (29, 30) .
Internalization assay
Internalization assay was performed as described previously (31) . Briefly, COS-7 cells in 12-well plates that had been transiently transfected were incubated at 37°C in serum-free DMEM with or without 1 μM Ang II for the indicated time. The cells were washed twice by ice-cold PBS and incubated for 3 h at 4°C with 0.1 nM -angiotensin II was removed using the acid wash technique of Crozat et al. (32) in which cells were exposed to 150 mM NaCl -50 mM glycine, pH 3, for 10 min at 4°C. The cell-associated radioactivity was measured by gamma counting.
Western blot analysis
Equal amounts of whole cell lysates were resolved by SDS-polyacrylamide gel electrophoresis and transferred onto Hybond ECL nitrocellulose membranes (Amersham Biosciences) using a semi dry system in immunotransfer buffer. The membranes were blocked in blocking buffer (Tris-buffered saline, TBS with 10% nonfat dried milk) and incubated for 1 h at room temperature. After blocking, membranes were exposed to AT 1 rabbit polyclonal IgG and actin rabbit polyclonal IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at 1:1000 dilutions in blocking buffer with 1% milk for 1 h and kept at 4°C for a whole night in a rotating shaker. The membranes were washed three times with TBS containing 0.1% Tween-20 and incubated with HRPconjugated anti-rabbit IgG (Promega, Madison, WI, USA) for 1 h at room temperature at 1:2000 dilutions in blocking buffer with 1% milk. The membranes were washed and then the blots on the membranes were visualized by adding Amersham ECL Western blotting detection reagent (GE Healthcare, Piscataway, NJ, USA).
Data analyses
Nonlinear regression analyses of saturation and competition binding assay were performed using GraphPad Prism software (San Diego, CA, USA). The results of experiments were expressed as the mean ± S.E.M. In competition binding experiments, the values of inhibition constants (K i ) were calculated by the following equation (33) : Table 1 ). The result demonstrated that the receptor expression for the mutant was decreased compared to WT AT 1 receptors (P<0.001). Table 2 shows the binding affinities (pK i ) for agonist and ARBs, valsartan, losartan, candesartan, and telmisartan, towards WT and N111G mutant of AT 1 receptors.
The binding affinity of Ang II to the mutant N111G was markedly increased compared to WT receptors (P<0.05) ( Table 2 , Fig. 1 ). ARBs showed 2 -3-fold decreased binding affinities to the mutant N111G compared to AT 1 WT receptor (P<0.05) ( Table 2) , although candesartan showed almost no change in binding affinity to the mutant. 
IP accumulation assay in transfected COS-7 cells
IP production was measured in COS-7 cells expressing both WT AT 1 and N111G mutant AT 1 receptors (Fig. 2) . Even though the level of expression of N111G mutant of AT 1 receptors (0.68 ± 0.12 pmol/mg of protein) was less than that of the WT (1.52 ± 0.07 pmol/mg of protein), the cells expressing the N111G mutant exhibited higher levels of agonist-independent (basal) IP production ( Fig. 2A) , showing constitutive activity. IP production by the cells expressing the N111G mutant AT 1 receptor was markedly decreased when incubated in the presence of the ARBs used in the study (Fig. 2B) .
Internalization of WT and N111G mutant of AT 1 receptors
In view of the apparent difference in G protein coupling and activation between WT AT 1 and N111G mutant AT 1 receptors, we examined the capacity of the mutant to undergo homologous internalization. Treatment of the WT and N111G mutant AT 1 receptors with 100 nM Ang II for 45 min induced 74.63 ± 1.00% and 19.56 ± 2.87% receptor internalization, respectively (Fig. 3) . Internalization of the N111G mutant AT 1 receptor was much lower than that of the WT AT 1 receptor (only 26% compared to the WT AT 1 receptor). However, when the ARB valsartan was used, internalization of the N111G mutant AT 1 receptor was significantly increased to 63.22 ± 0.38%, which is 3-fold higher than that of the N111G mutant in the absence of valsartan (Fig. 3) .
Western blot analysis
To investigate the expression of both WT and N111G mutant AT 1 receptors, we performed Western blot analysis. The Western blot probed with anti-AT 1 antibody detected the specified protein of the receptors, and immunoreactive bands were observed at 43 kDa in both WT and N111G mutant AT 1 receptors (Fig. 4) .
Discussion
Internalization plays an important role in receptor endocytosis and signal transduction. The present study demonstrated the correlation between endocytosis and signal transduction of AT 1 receptors due to its site directed mutagenesis. Homologous internalization of GPCRs is an active process that requires specific ligand binding, conformational changes of the receptor, and signal transduction initiated by the activated receptor (10). Earlier, it was reported that site directed mutagenesis of Asn 111 of TMD III of the AT 1 receptor to glycine (N111G) results in constitutive activation of the receptor (8) , and N111G showed higher basal IP production without agonist-induced stimulation compared to the WT AT 1 receptor. Thereby the present investigation has been performed to find out the correlation between the constitutive activity and internalization behavior of the N111G mutant receptor.
In saturation binding experiments, the data represent the different level of cell expression of N111G mutant receptor compared to WT AT 1 receptor. The mutant N111G showed a 2-fold lower B max value assessed by (Table 1 ). The competition binding experiment demonstrated that the binding affinity of the agonist, Ang II, was significantly increased for the N111G mutant compared to the WT AT 1 receptor, whereas the binding affinities of ARBs, valsartan, losartan, and telmisartan, were 2 -3-fold decreased towards the N111G mutant compared to the WT AT 1 receptor ( Table 2 , Fig. 1 ), although candesartan showed almost no change in binding affinity to the mutant. The results demonstrate that asparagine at position 111 of TMD III of the AT 1 receptor is a very important site for both agonist and antagonist binding.
IP production by the COS-7 cells expressing the WT and N111G mutant AT 1 receptor is shown in Fig. 2 . The results of IP production experiments show that N111G is a CAM (Fig. 2A) as described in the earlier study (8) . A decrease in the size of the Asn 111 side-chain induces an intermediate activated receptor conformation, which may be responsible for the constitutive activity of the N111G mutant (8) . Valsartan, losartan, candesartan, and telmisartan significantly suppressed the basal IP production by the cells expressing the constitutively active N111G mutant of AT 1 receptor (Fig. 2B) , which shows the inverse agonist activity of these compounds in the N111G mutant, although in a previous study, losartan was found to have weak inverse agonist activity in the same mutant (34) . Earlier studies suggest that the binding of inverse agonists not only blocks potential entry of Ang II into the receptor pocket but also induces the inactive conformation of the receptor (35) .
To determine the possible reason for the behavior of the N111G mutant AT 1 receptor in signaling transduction, the present study investigated internalization for cell localization of the receptor protein. The mutant N111G showed very low internalization behavior compared to WT AT 1 receptor after 45 min (Fig. 3) . However, it was very interesting that the internalization of N111G mutant significantly increased in the presence of valsartan. The AT 1 antagonist valsartan may cause a change in the conformation of the CAM N111G from the active to inactive state to promote internalization, which is consistent with the mechanism of inverse agonists of constitutive active GPCRs. Some GPCRs, such as vasopressin V2-, AT 1 -, and bradykinin B 2 -receptor subtypes, were reported to internalize upon antagonist binding (36 -38 In the present study, the N111G mutant of AT 1 receptor showed higher basal IP production without agonist-induced stimulation, which indicates that it might act like a CAM receptor. More interestingly, N111G showed very low internalization from the cell surface compared to WT AT 1 receptor. On the other hand, this mutant showed binding characteristics with Ang II and ARBs similar to those of the WT. The possible reason of these differential findings may be decreased size of the side chain due to the mutation of asparagine to glycine, which makes the receptor unable to bind with adaptor protein, resulting in the inability of the mutant receptor to undergo internalization and thus increased the amount of receptor protein on the cell surface. This in turn promotes higher IP production without agonist stimulation. Thus, our present study suggests that higher signal transduction by the mutant may be due to lack of sufficient internalization of the receptor from the cell surface. An earlier study (9) suggested that the conformation induced in the N111G mutant AT 1 receptor mimics the partially activated state (R') and transition to the fully activated conformation no longer requires Tyr 4 of Ang II. In the native AT 1 receptor, the R' conformation is generated by replacement with residues smaller than Asn
111
. Thus, when valsartan is used, the active conformation of the N111G mutant is again changed to the basal state of the receptor by the mechanism of inverse agonist activity of ARBs, which may in turn increase internalization of the receptor into the cell.
In summary, the N111G mutant AT 1 receptor can undergo ligand-induced internalization following stimulation of the ARB valsartan in COS-7 cells. If these results are applicable in vivo, the study may suggest that chronic treatment with valsartan may induce cell surface receptor losses, leading to apparent conditional knockout of receptor activity, this possibly being of clinical significance.
